Aldeyra’s ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Aldeyra Therapeutics Inc (NASDAQ:ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection,…
Aldeyra Therapeutics Schedules Conference Call And Webcast To Announce Top-Line Results From Part 1 Of The Phase 3 GUARD Trial Of ADX-2191 In Proliferative Vitreoretinopathy October 6
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3
Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell
• Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Earnings Outlook For Aldeyra Therapeutics
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement.
Analysts estimate that Aldeyra Therapeutics will report an earnings per share (EPS) of $-0.31.
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
